"ALS reversals": demographics, disease characteristics, treatments, and co-morbidities

At a glance

A study comparing patients with ALS reversals and those with usual ALS progression.

Affiliates

Daniel Harrison1, Paul Mehta2, Michael A. van Es3, Elijah Stommel4, Vivian E. Drory5, Beatrice Nefussy5, Leonard H. van den Berg3, Jesse Crayle1, Richard Bedlack6, and The Pooled Resource Open-Access ALS Clinical Trial Consortium

  1. School of Medicine, Duke University
  2. Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Services
  3. Department of Neurology, University Medical Center Utrecht
  4. Department of Neurology, Geisel School of Medicine at Dartmouth
  5. Department of Neurology, Tel-Aviv Medical Center
  6. Department of Neurology, Duke University and Durham VA Medical Center

Journal

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Summary

This study aims to identify differences in demographics, disease characteristics, treatments, and co-morbidities between patients with ALS reversals and those with the usual progression of ALS. Findings indicated that ALS reversals were more likely to be seen in PALS that are male, have limb onset disease, and initially progress faster. Moreover, the odds of having taken curcumin, lutein, cannabidiol, azathioprine, copper, glutathione, vitamin D, and fish oil were higher for those with ALS reversal compared to controls.

Link to paper

Find the paper here!

Print
Content Source:
Agency for Toxic Substances and Disease Registry